MED reports Q4, issues 2008 guidance

Reports net income of $0.04/share on revenues of $19.8 million.
Earned $0.28/share in 2007
Predicts 2008 earnings growth of 30-35%.

Today's closing price: $3.76

Mr. McDevitt concluded, "The Company believes, that due to the knowledge that was acquired through the advertising spend in 2007, that in 2008 we will devote a higher percentage of our marketing spend on higher returning advertising venues. These campaigns will include a mix of web, print, TV, radio, direct mail and other remarketing efforts, positioning us to achieve a superior return as we continue to more fully develop our multi-channel distribution model. With obesity rates soaring, there's never been a better time for a clinically-proven program for safe and sustained weight loss. Time after time when we look at our quantitative results next to those of other products and programs, we're seeing Medifast emerge with clear advantages, especially with regard to support, simplicity and fast, lasting results. 2008 promises even better products, better marketing, and more clinical data supporting our efforts -- and we look forward to the year ahead with great anticipation."

2008 Full-Year Guidance

Management expects revenue growth for full-year 2008 in the range of 8-10%; and diluted earnings per share growth in the range of 30-35% for the year ended December 31, 2008.


http://biz.yahoo.com/prnews/080312/law528.html?.v=2